In prostate cancer patients treated with androgen deprivation therapy (ADT) and radiation therapy (RT), a pre-RT PSA level X0.5 ng ml À 1 , determined after neoadjuvant ADT and before RT, predicts for worse survival measures. The present study sought to identify patient, tumor and treatment characteristics associated with the pre-RT PSA in prostate cancer patients. METHODS: We reviewed the charts of all patients diagnosed with intermediate-and high-risk prostate cancer and treated with a combination of neoadjuvant (median, 2.2 and 2.5 months, respectively), concurrent, and adjuvant ADT and RT between 1990 and 2011. RESULTS: A total of 170 intermediate-and 283 high-risk patients met inclusion criteria. On multivariate analysis, both intermediateand high-risk patients with higher pre-treatment PSA (iPSA) were significantly less likely to achieve a pre-RT PSA o0.5 ng ml À 1 (iPSA 10.1-20 ng ml
INTRODUCTION
Prostate cancer is the most commonly diagnosed cancer and the second leading cause of cancer death in American men. 1 The choice of treatment depends on patient factors (general health) and tumor factors (Gleason score, pre-treatment PSA (iPSA), clinical T stage). For men with clinically localized intermediate-and high-risk prostate cancer, the importance of combined modality therapy with androgen deprivation therapy (ADT) and radiation therapy (RT) has been well established in multiple randomized clinical trials. [2] [3] [4] [5] [6] In addition, dose-escalated RT (X74 Gy) has also been shown to demonstrate benefit in multiple randomized clinical trials. [7] [8] [9] As a result, a standard practice at our institution for the treatment of men with clinically localized intermediateand high-risk prostate cancer is ADT combined with doseescalated RT.
ADT is typically initiated in the neoadjuvant setting, administered concurrently with RT and continued in an adjuvant setting. Animal studies have shown that the effect of combined therapy is optimal when RT is delivered after maximal tumor reduction in response to neoadjuvant ADT. 10 This is in agreement with increasing clinical evidence that biochemical response to neoadjuvant ADT, as measured by PSA immediately before RT (pre-RT PSA), is an important predictive biomarker for the benefit of combined therapy. [11] [12] [13] [14] [15] [16] [17] [18] Similar findings have been observed in patients undergoing neoadjuvant ADT before radical prostatectomy, where biochemical response to neoadjuvant ADT, as measured by PSA immediately before prostatectomy, was likewise an important predictive biomarker for relapse. 19 Together, these observations imply that a failure to completely abrogate androgen receptor-mediated signaling might represent an intrinsic trait of some tumors and can be identified as early as 2-3 months after the initiation of neoadjuvant ADT.
To better understand the factors influencing biochemical response to androgen deprivation, the present study sought to identify the patient, tumor and treatment characteristics that may be used to predict the likelihood of achieving a pre-RT PSA of o0.5 ng ml À 1 in a large cohort of intermediate-and high-risk prostate cancer patients treated at a single institution.
MATERIALS AND METHODS

Study population
We reviewed the charts of all patients diagnosed with clinically localized intermediate-and high-risk prostate cancer treated with a combination of ADT and RT at the University of Texas MD Anderson Cancer Center between 1990 and 2011. Intermediate-and high-risk disease was defined in accordance with the D'Amico risk group stratification, that is, having at least one of the following criteria: 10o iPSA p20 ng ml À 1 , Gleason score 7 or clinical T stage T2b for intermediate-risk patients, and iPSA 420 ng ml À 1 , Gleason score X8 or clinical T stage XT2c for high-risk patients. 20 Additional inclusion criteria were (a) no evidence of metastatic disease, (b) 1.5-12 months of neoadjuvant ADT at the treating physician's discretion, (c) a pre-RT PSA level determined between 1.5 and 12 months after start of neoadjuvant ADT. A total of 170 intermediate-and 283 highrisk patients met inclusion criteria. The Institutional Review Board of the University of Texas MD Anderson Cancer Center approved the study protocol with a waiver of consent.
Hormone therapy
The neoadjuvant ADT was chosen at the treating physician's discretion and included luteinizing hormone-releasing hormone (LH-RH) agonist monotherapy, orchiectomy or total androgen blockade (LH-RH agonist combined with androgen receptor antagonist). The median duration of neoadjuvant ADT was 2.2 months (range, 1.5-10.0 months) for intermediate-risk patients and 2.5 months (range, 1.5-11.2 months) for high-risk patients. Patients on LH-RH monotherapy were given an androgen receptor antagonist for 14 days at the initiation of the LH-RH treatment to prevent flare at the discretion of the treating physician.
Statistical analysis
Summary statistics were used to describe patient (age, race, testosterone level), tumor (iPSA, clinical T stage, Gleason score) and treatment (duration of neoadjuvant ADT, type of neoadjuvant ADT, pre-RT PSA) characteristics. We used Fisher's exact test to test for differences between pre-RT PSA (o0.5 vs X0.5 ng ml À 1 ) groups for categorical variables and the Wilcoxon rank-sum test to compare medians between pre-RT PSA groups for continuous variables.
To identify factors associated with pre-RT PSA o0.5 ng ml À 1 , we used logistic regression analysis. All factors from the univariate analyses with P-values o0.25 were included in a multivariate model, and then backward elimination was used to remove factors until all remaining factors were significant at the 0.05 level.
All analyses were performed with SAS 9.1 for Windows (SAS Institute, Cary, NC, USA). 
Characteristics
All patients, N ¼ 170 Pre-RT PSA o0.5 ng ml ) are shown in Table 1 . The median age at diagnosis was significantly higher in the group with pre-RT PSA o0.5 ng ml À 1 compared with pre-RT PSA X0.5 ng ml À 1 group (71.2 vs 68.6, P ¼ 0.014). The percentage of men diagnosed with a Gleason score 7 was significantly higher in the group with pre-RT PSA o0.5 ng ml À 1 compared with pre-RT PSA X0.5 ng ml
group (95.8% vs 86.7%, P ¼ 0.002). The median iPSA was significantly higher in the pre-RT PSA X0.5 ng ml À 1 compared with pre-RT PSA o0.5 ng ml À 1 group (9.2 vs 6.3 ng ml À 1 , Po0.001). No differences were observed between the two groups with respect to other characteristics, including clinical T stage, duration of neoadjuvant ADT, type of neoadjuvant ADT, race and testosterone level (P40.05). Table 2 summarizes patient, tumor and treatment characteristics associated with achieving a pre-RT PSA o0.5 ng ml À 1 in intermediate-risk patients. Multivariate analysis revealed that increasing age (odds ratio (OR) ¼ 1.06, 95% confidence interval (CI) ¼ 1.01-1.12, P ¼ 0.013) was significantly associated with a pre-RT PSA o0.5 ng ml À 1 , whereas patients with higher iPSA (10.1-20 ng ml À 1 : OR ¼ 0.37, 95% CI ¼ 0.18-0.74, P ¼ 0.005) were significantly less likely to reach a pre-RT PSA o0.5 ng ml À 1 after neoadjuvant ADT.
Patient, tumor and treatment characteristics for the high-risk group summarized according to pre-RT PSA level (o0.5 vs X0.5 ng ml À 1 ) are shown in Table 3 . The median iPSA was significantly higher in the pre-RT PSA X0.5 ng ml À 1 compared with pre-RT PSA o0.5 ng ml À 1 group (21.3 vs 7.7 ng ml À 1 , Po0.001). The percentage of men with pre-RT PSA X0.5 ng ml À 1 compared with pre-RT PSA o0.5 ng ml À 1 was significantly higher for African-American men (78.0% vs 22.0%) than other men (53.3% vs 46.7%, P ¼ 0.004). The median testosterone level was significantly higher in the pre-RT PSA X0.5 ng ml À 1 compared with pre-RT PSA o0.5 ng ml À 1 group (32.0 vs 25.0 ng dl À 1 , P ¼ 0.013). No differences were observed between the two groups with respect to other characteristics, including age, clinical T stage, Gleason score, duration of neoadjuvant ADT and type of neoadjuvant ADT (P40.05). Table 4 summarizes the patient, tumor and treatment characteristics associated with achieving a pre-RT PSA o0.5 ng ml À 1 in high-risk patients. Multivariate analysis revealed that patients undergoing total androgen blockade (OR ¼ 1.84, 95% CI ¼ 1.06-3.21, P ¼ 0.031) were significantly more likely to achieve a pre-RT PSA o0.5 ng ml . However, as only 129 (45.6%) high-risk patients had testosterone data available, testosterone was not included in the multivariate model.
Because race was no longer statistically significant on multivariate analysis and type of neoadjuvant ADT became statistically significant in our multivariate model, we next examined whether there was an interaction between race and type of neoadjuvant ADT (LH-RH monotherapy/orchiectomy vs total androgen blockade). Indeed, we observed an interaction between race and type of neoadjuvant ADT when modeling pre-RT PSA in high-risk patients (P ¼ 0.074; Table 5 ). The type of neoadjuvant ADT was not found to significantly predict for pre-RT PSA level in non-AfricanAmerican men (pre-RT PSA o0.5 vs X0.5 ng ml À 1 : 45.3% vs 54.7% for LH-RH monotherapy/orchiectomy and 49.4% vs 50.6% for total androgen blockade; P ¼ 0.588). Conversely, although AfricanAmerican men on total androgen blockade reached pre-RT PSA o0.5 ng ml À 1 as frequently as non-African-American men on total compared with non-African-American men on LH-RH monotherapy/orchiectomy (13.3% vs 45.3%, respectively, P ¼ 0.001). In the subgroup of high-risk patients with testosterone data (B45% for both races), median pre-RT testosterone levels did not appear to differ significantly by race (P ¼ 0.37), or by race and type of neoadjuvant ADT (P ¼ 0.20 for LH-RH monotherapy/orchiectomy; P ¼ 0.74 for total androgen blockade).
DISCUSSION
We have previously reported a pre-RT PSA cut point of 0.5 ng ml À 1 as optimally discriminating failure-free survival, time to distant metastasis, prostate cancer-specific mortality and overall survival in high-risk prostate cancer patients treated with longterm ADT and dose-escalated RT. 16 In the present study, we performed an updated analysis of factors associated with achieving a pre-RT PSA of o0.5 ng ml À 1 in a much larger cohort of men, including intermediate-risk prostate cancer patients and more recently diagnosed high-risk prostate cancer patients. As at least one other report in the literature identified the PSA level of 0.5 ng ml À 1 after neoadjuvant ADT as a predictor of outcome in both high-and intermediate-risk prostate cancer patients, 12 we applied the same cut point to our intermediate-risk group as well. On multivariate analysis, older intermediate-risk patients were more likely to achieve a pre-RT PSA o0.5 ng ml
. This effect, although significant, was minor and might reflect hypogonadism with advancing age. Age was not found to be a predictor for pre-RT PSA level in men with high-risk prostate cancer. Although this may reflect inherent differences in tumor biology between the risk groups, it may also be due to generally smaller tumor burden in the intermediate-risk group, and therefore factors such as age might have relatively larger impact. Conversely, both intermediate-and high-risk patients with higher iPSA were less likely to achieve a pre-RT PSA o0.5 ng ml
. This finding is consistent with the previous reports, 11, 17 and could reflect inherent increased androgen receptor activity mediated by increased expression of androgen receptor coactivators or other ligand-independent mechanisms driving androgen receptor activation in these patients. Alternatively, it may also reflect increased tumor burden not appreciated on clinical exam.
Our previous multivariate analysis performed on 196 high-risk prostate cancer patients revealed that African-American men were significantly less likely to reach a pre-RT PSA o0.5 ng ml À 1 . 16 The present expanded analysis similarly found that 78.0% of AfricanAmerican high-risk patients had a pre-RT PSA X0.5 ng ml À 1 , and only 22.0% reached pre-RT PSA o0.5 ng ml À 1 . However, race no longer proved to be statistically significant on multivariate 
Characteristics
All patients, N ¼ 283 Pre-RT PSA o0.5 ng ml analysis. Instead, high-risk patients undergoing total androgen blockade proved to be associated with a pre-RT PSA o0.5 ng ml . Importantly, an interaction was present between race and type of neoadjuvant ADT in the group of high-risk patients. Although African-American men on total androgen blockade achieved a pre-RT PSA o0.5 ng ml À 1 as frequently as non-African-American men on total androgen blockade, AfricanAmerican men on LH-RH monotherapy were significantly less likely to reach pre-RT PSA o0.5 ng ml À 1 compared with nonAfrican-American men on LH-RH monotherapy. One possible explanation is that serum testosterone levels were not adequately suppressed by LH-RH monotherapy in African-American men compared with others. Examination of the median pre-RT testosterone levels available (approximately 45% of cases for both groups) did not detect a significant difference by race. However, these numbers were limited and require future study in prospective manner. Based on this, we caution that the biochemical response to neoadjuvant LH-RH monotherapy may be inferior in high-risk patients of African-American origin. Therefore, serum testosterone levels should be carefully monitored, and for those men who do not achieve castrate levels total androgen blockade with both an LH-RH agonist and an androgen receptor antagonist may be necessary to reach a pre-RT PSA o0.5 ng ml À 1 . Importantly, however, only B50% of patients on total androgen blockade reached pre-RT PSA o0.5 ng ml À 1 . This finding may suggest that castration-resistant mechanisms of androgen Abbreviations: ADT, androgen deprivation therapy; LH-RH, luteinizing hormone-releasing hormone; pre-RT PSA, pre-radiation therapy PSA.
Biochemical response to androgen deprivation JZ Cerne et al signaling are already at play in half of the patients and therefore demonstrates a need for clinical trials testing more aggressive androgen receptor axis blockade in the upfront setting in these patients.
Despite inherent limitations of a retrospective design, moderate number of African-American men and lack of uniform testosterone measurements, our results are largely consistent with previous reports and have potential implications for clinical management. Importantly, our results suggest that neoadjuvant total androgen blockade may be beneficial compared with LH-RH monotherapy in high-risk patients, particularly those with higher initial PSA, and highlight the need for routine testosterone monitoring in conjunction with PSA during neoadjuvant therapy. African-American men with high-risk prostate cancer should be closely observed for achieving castrate testosterone levels and adequately suppressed pre-RT PSA on LH-RH monotherapy. Men who do not achieve a pre-RT PSA o0.5 ng ml À 1 on total androgen blockade should be considered for clinical trials testing newer, more aggressive hormone-ablative therapies.
